Medication Abortion in the Courts: What’s at Stake? March 8, 2023 News Release Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000,…
New KFF Trackers Document State and Federal Reproductive Rights Litigation Across the Country February 23, 2023 News Release KFF has created two new trackers to follow swift-moving reproductive rights litigation in the state and federal courts. The tools, which are currently tracking the status of 21 state cases in 15 states and eight federal cases, will be updated regularly as the litigation proceeds. Major cases pending in federal…
State and Federal Reproductive Rights and Abortion Litigation Tracker February 17, 2023 Report This State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.
What Are the Exceptions to State Abortion Bans? May 18, 2023 News Release A new KFF analysis reviews exceptions to abortion bans and describes how the stated aim to provide life-saving and health-preserving abortion care may not be achieved in practice. Abortion is currently banned in 14 states and many other states have attempted to ban or severely restrict abortion access. Exceptions to…
A Review of Exceptions in State Abortions Bans: Implications for the Provision of Abortion Services May 18, 2023 Issue Brief This issue brief examines the varying exceptions (for life, health, rape/incest, and fatal fetal anomalies) in state abortion bans and restrictions and the complications that arise when pregnant people attempt to access abortion care under these exceptions.
Update on the Status of Medication Abortion and the Courts April 21, 2023 Blog This policy watch explains the April 21, 2023 United States Supreme Court’s ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA’s approval of mifepristone, the medication abortion pill.
Brief Examines Proposed Changes to Federal Anti-Discrimination Protections in Health Care that Would Limit Protections related to Gender Identity, Access to Abortion and Language Access July 1, 2019 News Release A new brief analyzes the Trump Administration’s proposed changes to federal anti-discrimination regulations that would eliminate existing protections in health care related to gender identity and access to abortion, and narrow protections for non-English speakers.
Data Note: Impact of New Title X Regulations on Network Participation September 20, 2019 Issue Brief This data note provides estimates of the status of the Title X network following the implementation of the new regulations.
Planned Parenthood Sites and Grantees Withdrawing From Title X If Court Doesn’t Block New Regulations August 16, 2019 Slide
Planned Parenthood Sites and Grantees Withdrawing from Title X Program If Court Does Not Block New Regulations August 15, 2019 Slide This map details the Planned Parenthood sites and grantees that will withdraw from the Title X family planning program if the 9th Circuit Federal Court of Appeals does not block the Trump Administration’s new Title X regulations by August 19, 2019.